世界のパーキンソン病治療薬市場インサイト及び予測(~2026年)

【英語タイトル】Global Parkinson’s Disease Drugs Market Insights and Forecast to 2026

QYResearchが出版した調査資料(QYR20NV08749)・商品コード:QYR20NV08749
・発行会社(調査会社):QYResearch
・発行日:2020年11月(※2024年版があります。お問い合わせください)
・ページ数:119
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートはパーキンソン病治療薬の世界市場について調査・分析した資料です。種類別(経口、経皮、皮下、腸内注入)の市場規模、用途別(病院薬局、小売薬局、オンライン薬局)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別パーキンソン病治療薬の競争状況、市場シェア
・世界のパーキンソン病治療薬市場:種類別市場規模 2015年-2020年(経口、経皮、皮下、腸内注入)
・世界のパーキンソン病治療薬市場:種類別市場規模予測 2021年-2026年(経口、経皮、皮下、腸内注入)
・世界のパーキンソン病治療薬市場:用途別市場規模 2015年-2020年(病院薬局、小売薬局、オンライン薬局)
・世界のパーキンソン病治療薬市場:用途別市場規模予測 2021年-2026年(病院薬局、小売薬局、オンライン薬局)
・北米のパーキンソン病治療薬市場分析:米国、カナダ
・ヨーロッパのパーキンソン病治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのパーキンソン病治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のパーキンソン病治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのパーキンソン病治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Novartis、F. Hoffmann-La Roche、AbbVie、Teva Pharmaceutical Industries、UCB Inc.、STADA Arzneimittel、GlaxoSmithKline、Bausch Health、Merck、Impax Laboratories
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Parkinson’s disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors.

Market Analysis and Insights: Global Parkinson’s Disease Drugs Market
The global Parkinson’s Disease Drugs market size is projected to reach US$ 2882.9 million by 2026, from US$ 2856 million in 2020, at a CAGR of 0.9%% during 2021-2026.

Global Parkinson’s Disease Drugs Scope and Market Size
Parkinson’s Disease Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinson’s Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Parkinson’s Disease Drugs market is segmented into
Oral
Transdermal
Subcutaneous
Intestinal Infusion

Segment by Application, the Parkinson’s Disease Drugs market is segmented into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Regional and Country-level Analysis
The Parkinson’s Disease Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Parkinson’s Disease Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Parkinson’s Disease Drugs Market Share Analysis
Parkinson’s Disease Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Parkinson’s Disease Drugs business, the date to enter into the Parkinson’s Disease Drugs market, Parkinson’s Disease Drugs product introduction, recent developments, etc.

The major vendors covered:
Novartis
F. Hoffmann-La Roche
AbbVie
Teva Pharmaceutical Industries
UCB Inc.
STADA Arzneimittel
GlaxoSmithKline
Bausch Health
Merck
Impax Laboratories

【レポートの目次】

1 Study Coverage
1.1 Parkinson’s Disease Drugs Product Introduction
1.2 Market Segments
1.3 Key Parkinson’s Disease Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Parkinson’s Disease Drugs Market Size Growth Rate by Type
1.4.2 Oral
1.4.3 Transdermal
1.4.4 Subcutaneous
1.4.5 Intestinal Infusion
1.5 Market by Application
1.5.1 Global Parkinson’s Disease Drugs Market Size Growth Rate by Application
1.5.2 Hospital Pharmacy
1.5.3 Retail Pharmacy
1.5.4 Online Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Parkinson’s Disease Drugs Market Size, Estimates and Forecasts
2.1.1 Global Parkinson’s Disease Drugs Revenue 2015-2026
2.1.2 Global Parkinson’s Disease Drugs Sales 2015-2026
2.2 Global Parkinson’s Disease Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Parkinson’s Disease Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Parkinson’s Disease Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Parkinson’s Disease Drugs Competitor Landscape by Players
3.1 Parkinson’s Disease Drugs Sales by Manufacturers
3.1.1 Parkinson’s Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Parkinson’s Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Parkinson’s Disease Drugs Revenue by Manufacturers
3.2.1 Parkinson’s Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Parkinson’s Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Parkinson’s Disease Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Parkinson’s Disease Drugs Revenue in 2019
3.2.5 Global Parkinson’s Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Parkinson’s Disease Drugs Price by Manufacturers
3.4 Parkinson’s Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Parkinson’s Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Parkinson’s Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Parkinson’s Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Parkinson’s Disease Drugs Market Size by Type (2015-2020)
4.1.1 Global Parkinson’s Disease Drugs Sales by Type (2015-2020)
4.1.2 Global Parkinson’s Disease Drugs Revenue by Type (2015-2020)
4.1.3 Parkinson’s Disease Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Parkinson’s Disease Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Parkinson’s Disease Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Parkinson’s Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Parkinson’s Disease Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Parkinson’s Disease Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Parkinson’s Disease Drugs Market Size by Application (2015-2020)
5.1.1 Global Parkinson’s Disease Drugs Sales by Application (2015-2020)
5.1.2 Global Parkinson’s Disease Drugs Revenue by Application (2015-2020)
5.1.3 Parkinson’s Disease Drugs Price by Application (2015-2020)
5.2 Parkinson’s Disease Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Parkinson’s Disease Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Parkinson’s Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Parkinson’s Disease Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Parkinson’s Disease Drugs by Country
6.1.1 North America Parkinson’s Disease Drugs Sales by Country
6.1.2 North America Parkinson’s Disease Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Parkinson’s Disease Drugs Market Facts & Figures by Type
6.3 North America Parkinson’s Disease Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Parkinson’s Disease Drugs by Country
7.1.1 Europe Parkinson’s Disease Drugs Sales by Country
7.1.2 Europe Parkinson’s Disease Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Parkinson’s Disease Drugs Market Facts & Figures by Type
7.3 Europe Parkinson’s Disease Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Parkinson’s Disease Drugs by Region
8.1.1 Asia Pacific Parkinson’s Disease Drugs Sales by Region
8.1.2 Asia Pacific Parkinson’s Disease Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Parkinson’s Disease Drugs Market Facts & Figures by Type
8.3 Asia Pacific Parkinson’s Disease Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Parkinson’s Disease Drugs by Country
9.1.1 Latin America Parkinson’s Disease Drugs Sales by Country
9.1.2 Latin America Parkinson’s Disease Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Parkinson’s Disease Drugs Market Facts & Figures by Type
9.3 Central & South America Parkinson’s Disease Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Parkinson’s Disease Drugs by Country
10.1.1 Middle East and Africa Parkinson’s Disease Drugs Sales by Country
10.1.2 Middle East and Africa Parkinson’s Disease Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Parkinson’s Disease Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Parkinson’s Disease Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Description and Business Overview
11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis Parkinson’s Disease Drugs Products Offered
11.1.5 Novartis Related Developments
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Corporation Information
11.2.2 F. Hoffmann-La Roche Description and Business Overview
11.2.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.2.4 F. Hoffmann-La Roche Parkinson’s Disease Drugs Products Offered
11.2.5 F. Hoffmann-La Roche Related Developments
11.3 AbbVie
11.3.1 AbbVie Corporation Information
11.3.2 AbbVie Description and Business Overview
11.3.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.3.4 AbbVie Parkinson’s Disease Drugs Products Offered
11.3.5 AbbVie Related Developments
11.4 Teva Pharmaceutical Industries
11.4.1 Teva Pharmaceutical Industries Corporation Information
11.4.2 Teva Pharmaceutical Industries Description and Business Overview
11.4.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Teva Pharmaceutical Industries Parkinson’s Disease Drugs Products Offered
11.4.5 Teva Pharmaceutical Industries Related Developments
11.5 UCB Inc.
11.5.1 UCB Inc. Corporation Information
11.5.2 UCB Inc. Description and Business Overview
11.5.3 UCB Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 UCB Inc. Parkinson’s Disease Drugs Products Offered
11.5.5 UCB Inc. Related Developments
11.6 STADA Arzneimittel
11.6.1 STADA Arzneimittel Corporation Information
11.6.2 STADA Arzneimittel Description and Business Overview
11.6.3 STADA Arzneimittel Sales, Revenue and Gross Margin (2015-2020)
11.6.4 STADA Arzneimittel Parkinson’s Disease Drugs Products Offered
11.6.5 STADA Arzneimittel Related Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Corporation Information
11.7.2 GlaxoSmithKline Description and Business Overview
11.7.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.7.4 GlaxoSmithKline Parkinson’s Disease Drugs Products Offered
11.7.5 GlaxoSmithKline Related Developments
11.8 Bausch Health
11.8.1 Bausch Health Corporation Information
11.8.2 Bausch Health Description and Business Overview
11.8.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Bausch Health Parkinson’s Disease Drugs Products Offered
11.8.5 Bausch Health Related Developments
11.9 Merck
11.9.1 Merck Corporation Information
11.9.2 Merck Description and Business Overview
11.9.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Merck Parkinson’s Disease Drugs Products Offered
11.9.5 Merck Related Developments
11.10 Impax Laboratories
11.10.1 Impax Laboratories Corporation Information
11.10.2 Impax Laboratories Description and Business Overview
11.10.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Impax Laboratories Parkinson’s Disease Drugs Products Offered
11.10.5 Impax Laboratories Related Developments
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Description and Business Overview
11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis Parkinson’s Disease Drugs Products Offered
11.1.5 Novartis Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Parkinson’s Disease Drugs Market Estimates and Projections by Region
12.1.1 Global Parkinson’s Disease Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Parkinson’s Disease Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Parkinson’s Disease Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Parkinson’s Disease Drugs Sales Forecast (2021-2026)
12.2.2 North America: Parkinson’s Disease Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Parkinson’s Disease Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Parkinson’s Disease Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Parkinson’s Disease Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Parkinson’s Disease Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Parkinson’s Disease Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Parkinson’s Disease Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Parkinson’s Disease Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Parkinson’s Disease Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Parkinson’s Disease Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Parkinson’s Disease Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Parkinson’s Disease Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Parkinson’s Disease Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Parkinson’s Disease Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Parkinson’s Disease Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Parkinson’s Disease Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Parkinson’s Disease Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Parkinson’s Disease Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Parkinson’s Disease Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Parkinson’s Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Parkinson’s Disease Drugs Market Segments
Table 2. Ranking of Global Top Parkinson’s Disease Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Parkinson’s Disease Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Oral
Table 5. Major Manufacturers of Transdermal
Table 6. Major Manufacturers of Subcutaneous
Table 7. Major Manufacturers of Intestinal Infusion
Table 8. Global Parkinson’s Disease Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Parkinson’s Disease Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Parkinson’s Disease Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Parkinson’s Disease Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Parkinson’s Disease Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Parkinson’s Disease Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Parkinson’s Disease Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Parkinson’s Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Parkinson’s Disease Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinson’s Disease Drugs as of 2019)
Table 17. Parkinson’s Disease Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Parkinson’s Disease Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Parkinson’s Disease Drugs Price (2015-2020) (USD/Unit)
Table 20. Parkinson’s Disease Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Parkinson’s Disease Drugs Product Type
Table 22. Date of International Manufacturers Enter into Parkinson’s Disease Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Parkinson’s Disease Drugs Sales Share by Type (2015-2020)
Table 26. Global Parkinson’s Disease Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Parkinson’s Disease Drugs Revenue Share by Type (2015-2020)
Table 28. Parkinson’s Disease Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 30. Global Parkinson’s Disease Drugs Sales Share by Application (2015-2020)
Table 31. North America Parkinson’s Disease Drugs Sales by Country (2015-2020) (K Units)
Table 32. North America Parkinson’s Disease Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Parkinson’s Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Parkinson’s Disease Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 36. North America Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 38. North America Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Parkinson’s Disease Drugs Sales by Country (2015-2020) (K Units)
Table 40. Europe Parkinson’s Disease Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Parkinson’s Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Parkinson’s Disease Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 44. Europe Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 46. Europe Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Parkinson’s Disease Drugs Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Parkinson’s Disease Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Parkinson’s Disease Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Parkinson’s Disease Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Parkinson’s Disease Drugs Sales by Country (2015-2020) (K Units)
Table 56. Latin America Parkinson’s Disease Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Parkinson’s Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Parkinson’s Disease Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 60. Latin America Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 62. Latin America Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Parkinson’s Disease Drugs Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Parkinson’s Disease Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Parkinson’s Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Parkinson’s Disease Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Parkinson’s Disease Drugs Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Parkinson’s Disease Drugs Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Table 71. Novartis Corporation Information
Table 72. Novartis Description and Major Businesses
Table 73. Novartis Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Novartis Product
Table 75. Novartis Recent Development
Table 76. F. Hoffmann-La Roche Corporation Information
Table 77. F. Hoffmann-La Roche Description and Major Businesses
Table 78. F. Hoffmann-La Roche Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. F. Hoffmann-La Roche Product
Table 80. F. Hoffmann-La Roche Recent Development
Table 81. AbbVie Corporation Information
Table 82. AbbVie Description and Major Businesses
Table 83. AbbVie Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. AbbVie Product
Table 85. AbbVie Recent Development
Table 86. Teva Pharmaceutical Industries Corporation Information
Table 87. Teva Pharmaceutical Industries Description and Major Businesses
Table 88. Teva Pharmaceutical Industries Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Teva Pharmaceutical Industries Product
Table 90. Teva Pharmaceutical Industries Recent Development
Table 91. UCB Inc. Corporation Information
Table 92. UCB Inc. Description and Major Businesses
Table 93. UCB Inc. Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. UCB Inc. Product
Table 95. UCB Inc. Recent Development
Table 96. STADA Arzneimittel Corporation Information
Table 97. STADA Arzneimittel Description and Major Businesses
Table 98. STADA Arzneimittel Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. STADA Arzneimittel Product
Table 100. STADA Arzneimittel Recent Development
Table 101. GlaxoSmithKline Corporation Information
Table 102. GlaxoSmithKline Description and Major Businesses
Table 103. GlaxoSmithKline Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. GlaxoSmithKline Product
Table 105. GlaxoSmithKline Recent Development
Table 106. Bausch Health Corporation Information
Table 107. Bausch Health Description and Major Businesses
Table 108. Bausch Health Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Bausch Health Product
Table 110. Bausch Health Recent Development
Table 111. Merck Corporation Information
Table 112. Merck Description and Major Businesses
Table 113. Merck Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Merck Product
Table 115. Merck Recent Development
Table 116. Impax Laboratories Corporation Information
Table 117. Impax Laboratories Description and Major Businesses
Table 118. Impax Laboratories Parkinson’s Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. Impax Laboratories Product
Table 120. Impax Laboratories Recent Development
Table 121. Global Parkinson’s Disease Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 122. Global Parkinson’s Disease Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 123. Global Parkinson’s Disease Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 124. Global Parkinson’s Disease Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 125. North America: Parkinson’s Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 126. North America: Parkinson’s Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Europe: Parkinson’s Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 128. Europe: Parkinson’s Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Asia Pacific: Parkinson’s Disease Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 130. Asia Pacific: Parkinson’s Disease Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 131. Latin America: Parkinson’s Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 132. Latin America: Parkinson’s Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Middle East and Africa: Parkinson’s Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Middle East and Africa: Parkinson’s Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 136. Key Challenges
Table 137. Market Risks
Table 138. Main Points Interviewed from Key Parkinson’s Disease Drugs Players
Table 139. Parkinson’s Disease Drugs Customers List
Table 140. Parkinson’s Disease Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Parkinson’s Disease Drugs Product Picture
Figure 2. Global Parkinson’s Disease Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Oral Product Picture
Figure 4. Transdermal Product Picture
Figure 5. Subcutaneous Product Picture
Figure 6. Intestinal Infusion Product Picture
Figure 7. Global Parkinson’s Disease Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital Pharmacy
Figure 9. Retail Pharmacy
Figure 10. Online Pharmacy
Figure 11. Parkinson’s Disease Drugs Report Years Considered
Figure 12. Global Parkinson’s Disease Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Parkinson’s Disease Drugs Sales 2015-2026 (K Units)
Figure 14. Global Parkinson’s Disease Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Parkinson’s Disease Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Parkinson’s Disease Drugs Sales Market Share by Region in 2019
Figure 17. Global Parkinson’s Disease Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Parkinson’s Disease Drugs Revenue Market Share by Region in 2019
Figure 19. Global Parkinson’s Disease Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Parkinson’s Disease Drugs Revenue in 2019
Figure 21. Parkinson’s Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Parkinson’s Disease Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Parkinson’s Disease Drugs Sales Market Share by Type in 2019
Figure 24. Global Parkinson’s Disease Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Parkinson’s Disease Drugs Revenue Market Share by Type in 2019
Figure 26. Global Parkinson’s Disease Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Parkinson’s Disease Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Parkinson’s Disease Drugs Sales Market Share by Application in 2019
Figure 29. Global Parkinson’s Disease Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Parkinson’s Disease Drugs Revenue Market Share by Application in 2019
Figure 31. North America Parkinson’s Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Parkinson’s Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Parkinson’s Disease Drugs Sales Market Share by Country in 2019
Figure 34. North America Parkinson’s Disease Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Parkinson’s Disease Drugs Market Share by Type in 2019
Figure 40. North America Parkinson’s Disease Drugs Market Share by Application in 2019
Figure 41. Europe Parkinson’s Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Parkinson’s Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Parkinson’s Disease Drugs Sales Market Share by Country in 2019
Figure 44. Europe Parkinson’s Disease Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Parkinson’s Disease Drugs Market Share by Type in 2019
Figure 56. Europe Parkinson’s Disease Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Parkinson’s Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Parkinson’s Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Parkinson’s Disease Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Parkinson’s Disease Drugs Revenue Market Share by Region in 2019
Figure 61. China Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Parkinson’s Disease Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Parkinson’s Disease Drugs Market Share by Application in 2019
Figure 85. Latin America Parkinson’s Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Parkinson’s Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Parkinson’s Disease Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Parkinson’s Disease Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Parkinson’s Disease Drugs Market Share by Type in 2019
Figure 96. Latin America Parkinson’s Disease Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Parkinson’s Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Parkinson’s Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Parkinson’s Disease Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Parkinson’s Disease Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Parkinson’s Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Parkinson’s Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Parkinson’s Disease Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Parkinson’s Disease Drugs Market Share by Application in 2019
Figure 109. North America Parkinson’s Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Parkinson’s Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Parkinson’s Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Parkinson’s Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Parkinson’s Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Parkinson’s Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Parkinson’s Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Parkinson’s Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Parkinson’s Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Parkinson’s Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed


【掲載企業】

Novartis、F. Hoffmann-La Roche、AbbVie、Teva Pharmaceutical Industries、UCB Inc.、STADA Arzneimittel、GlaxoSmithKline、Bausch Health、Merck、Impax Laboratories

★調査レポート[世界のパーキンソン病治療薬市場インサイト及び予測(~2026年)] (コード:QYR20NV08749)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のパーキンソン病治療薬市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆